
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$250M to $500M
Estimated OwnershipPublicMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.